THE cAMP pathway represents an important signaling pathway involved in many aspects of cell regulation. An increasing number of examples now in the literature link its deregulation to disease and suggest that agents that can restore normal signaling by targeting components of the cAMP signaling pathway have therapeutic potential. Examples include Alzheimer's disease (24) ; cardiovascular diseases such as atherosclerosis, restenosis, and reperfusion injury (9) ; diabetes (6, 10, 11, 27) ; depression (23) ; and cancer (3, 4) . Chromosome 6 open reading frame 176 (C6orf176), a new, primate-specific gene of unknown function, was identified in previous genome-wide expression studies by strong upregulation of its expression subsequent to activation of the cAMP signaling pathway following treatment of human ciliary smooth muscle (hCSM) cells with prostaglandin E 2 receptor subtype EP2-and EP4-specific agonists (19) . These agonists, AGN007 and AGN008, respectively, with improved receptor affinity and specificity characteristics are being developed as next generation ocular hypotensive antiglaucoma agents enhancing uveo-scleral outflow via activation of the cAMP pathway. They bind to the EP2 and EP4 prostanoid receptors, which are two of the four known subtypes (EP1-4). Both of these receptors couple to Gs and mediate increases in cAMP concentration, in contrast to the Gi coupling of EP3 and the Gq coupling of EP1 receptors (18, 22) . The cAMP-response element binding protein (CREB) family of activators stimulate cellular gene expression after cAMP-dependent protein kinasemediated phosphorylation (15) . In our experimental conditions, the most pronounced transcriptional upregulation by far was observed for C6orf176, which may serve as a biomarker and/or pharmaceutical drug target in context of diseases with deregulated cAMP signaling.
The National Center for Biotechnology Information (NCBI) has recently reclassified the C6orf176 gene as a noncoding RNA (ncRNA) and lists two transcript variants that share the first exon: transcript variant 1 (tv1; accession number: NR_026860) and transcript variant 2 (tv2; accession number: NR_026861). ncRNA is emerging as an important regulator of gene expression in many organisms. Some ncRNAs that trigger different types of gene silencing are collectively referred to as RNA silencing or RNA interference (RNAi). Here, we present evidence, based on qRT-PCR, Northern blot analysis, as well as cDNA library screening, for existence of additional C6orf176 transcript variants [whose observed open reading frames (ORFs) could be translated], and discuss possible RNAi-mediated regulatory functions upon expression of other genes that are part of cell type-specific networks mediating physiological effects in response to cAMP signaling.
EXPERIMENTAL PROCEDURES
Materials. Agents used to activate various cell surface receptors as well as adenylate cyclase were prepared in 10 mM dimethyl sulfoxide (DMSO) stock solutions. The EP2 agonist AGN007 and the EP4 agonist AGN008 were synthesized at Allergan (Irvine, CA). The prostaglandin E2 receptor pan-agonist PGE 2, the DP1 receptor agonist BW 245C, the FP receptor agonist PGF2␣, the IP receptor agonist carbacyclin, the ␣2-adrenergic receptor agonist brimonidine tartrate, the dopamine DRD2 receptor agonist (Ϯ)-quinpirole dihydrochloride (QDC), the thromboxane A2 receptor agonist U46619, and the adenylate cyclase activator forskolin were purchased from Sigma-Aldrich and EMD Chemicals. Growth media, fetal bovine serum (FBS), L-glutamine, geneticin (G418), and antibiotic/antimycotic (10,000 units/ml penicillin G, 10,000 units/ml streptomycin sulphate, 25 g/ml amphotericin B in 0.85% saline), were purchased from Gibco. DMSO, indomethacin, fatty acid-free bovine serum albumin (BSA), and transferrin were acquired from Sigma. Various commercially available kits were obtained as specified below.
Cell cultures. hCSM and human embryonic kidney-293 cells heterologously expressing a human recombinant EP2 receptor (HEK-293/hEP2) were established and cultured as described in Reitmair et al. (19) . TM86 were primary trabecular meshwork cells isolated as described previously (21) 1% antibiotic/antimycotic, transferrin (4 g/ml), fatty acid-free BSA (20 g/ml), and indomethacin (0.1 M). Indomethacin was added separately on the day of starvation treatment. Subsequently, the medium was exchanged with an incubation medium, which consisted of MEM (D-Valine), 1% L-glutamine, 1% antibiotic/antimycotic, and transferrin (4 g/ml). We began drug treatment for the specified time periods began by adding the respective amounts of each drug into dishes. Untreated controls received equal amounts of DMSO. The experiments with TM86, ARPE-19, and HEK-293 cells were performed using the cell lines' respective growth media.
Quantitative real-time reverse transcriptase-polymerase chain reaction. For quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), total RNA from cells was isolated as described previously (19) . qRT-PCR assays were performed using an ABI Prism 7700 thermocycler (Applied Biosystems, Foster City, CA) with 100 ng of total RNA as template input in 25 l total volume per reaction in 96-well plate format along with template-free negative controls. Primers and probes for each gene (TaqMan Gene Expression Assays) and TaqMan One-Step PCR Master Mix Reagents kits, containing a TaqMan Universal PCR master mix, a Multiscribe reverse transcriptase, and an RNase inhibitor mix, were obtained from Applied Biosystems. Final primer and probe concentrations were 200 and 900 nM, respectively. In addition to the commercially available primer and probe set for C6orf176 (Hs00293257_m1) which monitors tv1, custom-designed primer and probe sets, based on publicly available genomic sequence information from the human genome reference assembly NCBI Build 36.3, were obtained through Applied Biosystems's Assays-by-Design service and are listed in Table 1 . A reverse transcription step of 31 min at 48°C was followed by 10 min at 95°C, as well as 40 cycles of 15 s at 95°C denaturation and 1 min at 60°C hybridization/extension. Amplification plots were analyzed using the Sequence Detection System version 1.9.1 software (Applied Biosystems) to determine threshold cycles (C t) of amplification detection. Triplicate qRT-PCR analysis was performed for each gene of interest based on RNA materials derived from at least three biologically independent experiments. Relative gene expression ratios in treated vs. untreated samples (fold changes of transcript levels) were calculated based on the comparative Ct method (⌬⌬Ct method) (13) using GAPDH and beta-actin controls included in each real-time RT-PCR run. P values are based on two-sided two-sample Student's t-tests for the null hypothesis of no difference compared with controls. Data are expressed as means Ϯ SE.
Preparation of Northern blot probes. Complementary DNA probes for C6orf176 exon 1 and human GAPDH were labeled with [␣-32 P]dCTP (6,000 Ci/mmol, PerkinElmer) using the Prime-It II Random Primer Labeling Kit (Stratagene/Agilent Technologies) according to the manufacturer's recommendation with the following modification. To selectively obtain gene-specific radioactively labeled antisense probes, the random oligonucleotide primers provided with the kit were replaced by custom-synthesized (Integrated DNA Technologies) gene-specific antisense primers (C6orf176_L12: 5=-actgcgcaaagc, and GAPDH_L12: 5=-atccgttgactc, respectively).
DNA template to be labeled consisted of custom-synthesized oligo sequences (C6orf176_ex1_200nt, 5=-gctttccccg agacccccag atggaaagga gggaaggagg aaccccacac actcgccttt tgcgagaaga tcggcgcgca ccccagagtg ccccaagcct ttggaatctg cctgctgagc ggagcgcgcg agcgtggtgg acaggtcccg aacttggcca gcgggctttc ttggcaactt gctttgcgca gttctccatg; and GAPDH_80nt, 5=-tcttcttttg cgtcgccagc cgagccacat cgctcagaca ccatggggaa ggtgaaggtc ggagtcaacg gatttggtcg, respectively), which were selected subsequent to BLAST searches for minimization of sequence homologies to other RNA sequences in the human transcriptome. We annealed 50 pmol of probe to 0.4 pmol of template, followed by 10 min of Exo(-) Klenow enzyme-mediated DNA synthesis at 40°C and purification by NucTrap Probe Purification Columns (Stratagene/Agilent Technologies).
RNA isolation and northern blot analysis. Naïve HEK-293 cells as well as HEK-293 cells stably overexpressing the hEP2 receptor (HEK-293/hEP2) were grown to confluence in 15 cm dishes, followed by starvation in absence of FBS and presence of 100 nM of the cyclooxygenase inhibitor indomethacin, 20 g/ml fatty acid-free BSA, and 4 g/ml transferrin for 22 h. Cells were then exposed for 2 h to 200 nM of the EP2 agonist AGN007 (HEK-293/hEP2 cells) or the corresponding amount of DMSO (HEK-293 naïve cells) in the absence of FCS and presence of transferrin. The FastTrack MAG mRNA Isolation Kit (Invitrogen) was used to isolate high-quality mRNA according to the manufacturer's recommendation with the exception of an extended separation period (overnight at 4°C) of mRNA-bound magnetic beads in the magnetic separator. mRNA was quantitated using a spectrophotometer ND-1000 (Nanodrop Technologies). Its quality was assessed regarding purity and stability using a Bioanalyzer 2100 (Agilent Technologies). 
TaqMan-based primer and probe sets were designed to monitor transcription of chromosome 6 open reading frame 176 (C6orf176) transcript variant 2 (tv2) (set a), a putative alternatively spliced exon (set b) based on expressed sequence tag (EST) sequence information, and an Image cDNA clone (accession number: CB985684), the hypothetical gene LOC441177 based on an Image cDNA clone (accession number: BC110806) in antisense direction that partially overlap the transcribed C6orf176 exon 1 region (set c), and another putative gene in antisense orientation (hmm409034) located ϳ3.5 kb further upstream (set d). The minor groove binding probe oligonucleotides have a 6-carboxy fluorescein (FAM) fluorescent dye attached to their 5=-ends and a nonfluorescent quencher (NFQ) at their 3=-ends.
The Ambion NorthernMax Kit was used to perform the Northern blot following the manufacturer's protocol with the subsequent conditions. We loaded 19 g of mRNA per lane onto a denaturing 1% agarose-formaldehyde gel and electrophoresed for 3.5 h at 80 V. Two RNA molecular weight markers (Sigma and Ambion) containing 125 ng/ml ethidium bromide were also run on the gel to estimate transcript size. A downward capillary blot was used to transfer mRNA to a BrightStar-Plus (Ambion) positively-charged nylon membrane and immobilized using an ultraviolet crosslinker (UV Stratalinker 2400; Stratagene/Agilent Technologies). The blot was mixed with ULTRAhyb buffer from the NorthernMax kit and allowed to prehybridize for 40 min at 60°C. The C6orf176 exon 1-specific radioactive probe was heated to 95°C for 10 min and added to the buffer, followed by hybridization for 20 h at 60°C. After hybridization, the membrane was washed twice with low-stringency buffer for 5 min at room temperature, then washed twice with high -buffer (45°C for 15 min and 55°C for 20 min), and subsequently exposed to BioMax XAR film (Kodak) at Ϫ80°C using an intensifying screen (Kodak). After analysis, the membrane was stripped with boiling RNase-free water containing 0.1% SDS and hybridized to the GAPDH-specific probe for 18 h at 50°C, followed by two washes with low stringency (5 min at room temperature), three washes with high stringency buffer (45°C for 15 min twice, and 50°C for 20 min), and exposure to film.
cDNA library construction. A cDNA library was constructed based on mRNA extracted from 1 ϫ 10 7 hCSM cells after treatment with the EP2 agonist AGN007 (0.2 M) for 2 h, followed by mRNA extraction using Invitrogen's FastTrack MAG mRNA Isolation Kit (version C) according to the manufacturer's protocol, which included treatment with DNaseI. We used 4 g mRNA as starting material for subsequent cDNA library construction using Invitrogen's CloneMiner II cDNA Library Construction Kit according to the manufacturer's instructions. Single-stranded mRNA was converted into double-stranded cDNA containing attB sequences on each end. Through site-specific recombination, attB-flanked cDNA was cloned directly into an attP-containing donor vector. Competent ElectroMAX DH10B T1 Phage resistant cells were transformed, and a plating assay was performed. Library titer and yield for the EP2 agonist-induced cDNA library were 3 ϫ 10 7 cfu/ml and 3.6 ϫ 10 8 cfu, respectively. Individual colonies were grown overnight in LB medium containing 50 g/ml kanamycin, followed by plasmid isolation using Invitrogen's PureLink Quick Plasmid MiniPrep Kit according to the manufacturer's protocol. Plasmid DNAs were subjected to a BsrG I restriction enzyme digest followed by 1% agarose gel electrophoresis to evaluate cDNA inserts. The recombination rate was determined at Ͼ80%.
cDNA library screening by hybridization with a radiolabeled probe. The EP2 agonist-induced cDNA library propagated as plasmids in bacteria was plated onto 15 cm agar plates containing 50 g/ml kanamycin at various densities (200,000 -400,000 clones per plate) and grown overnight at 37°C. After 1 h at 4°C, BrightStar-Plus (Ambion) positively charged nylon membranes were placed in duplicate onto agar plates, marked, lifted, and autoclaved for 1 min at 121°C with a quick-exhaust program to lyse the cells. Positive control (C6orf176_ex1_200nt) and negative control DNA oligos (GAPDH_ 80nt) were spotted onto nylon membranes followed by UV crosslink- Assay information was compiled from the corresponding assay information files obtained from Applied Biosystems and includes ␤-actin and GAPDH controls. As exact sequence information for proprietary primer and probe sets was not disclosed, only probe context sequence is shown.
ing (UV Stratalinker 2400, Stratagene/Agilent Technologies). Prehybridization was performed for 45 min at 42°C in ULTRAhyb buffer (Ambion). The C6orf176 exon 1-specific radioactive probe, described above, was heated to 95°C for 10 min and then added to the prehybridization solution. The hybridization was allowed to continue for 30 h at 42°C. Subsequently, membranes were washed twice with low-stringency wash buffer (Ambion) for 5 min at room temperature, then washed twice with high-stringency wash buffer (Ambion) at 42°C for 20 min, and exposed to BioMax XAR film (Kodak) at Ϫ80°C for 2-5 days using an intensifying screen (Kodak).
For isolation of positive clones, round pieces (4 mm diameter) were cut out from primary screen agar plates, placed into 200 l of S.O.C. medium (Invitrogen), heated for 5 min at 37°C, vortexed, and replated at low densities (200 -800 clones per plate). Secondary screening by hybridization with the C6orf176 exon 1-specific radiolabeled probe was carried out as described above. Isolated individual positive colonies were picked and grown overnight at 37°C in 5 ml TB medium containing 50 g/ml kanamycin. Plasmids were isolated using Invitrogen's PureLink Quick Plasmid MiniPrep Kit according to the manufacturer's protocol. Plasmid DNA was quantitated and its quality assessed using a spectrophotometer ND-1000 (Nanodrop Technologies). Insert sequencing with at least twofold coverage was performed using M13 forward and M13reverse primers as well as primers specific for insert sequences.
RNAi-based gene silencing experiments. hCSM cells were set up as described above and transfected with double-stranded small interfering (si) RNA molecules (Stealth RNAi, Invitrogen) using Lipofectamine 2000 (Invitrogen). The transfection procedure followed the manufacturer's recommendations and was optimized using the BLOCK-iT Alexa Fluor Red Fluorescent Oligo (Invitrogen), an Alexa Fluor 555-labeled RNA duplex designed for use as a tool for siRNA uptake assessment. RNAi molecules were designed using Invitrogen's online BLOCK-iT RNAi designer tool. A total of 20 siRNA duplexes were tested and a combination of the four most effective siRNA duplexes selected. Sequences were: 5=-UUCAUCGUGAUGCAUCUCCCG-GCGC, 5=-UUAAACUGGAUCUUUGCAGACAGGG, 5=-GCUACA-GACGUCAUCGCCUCCUGUU, and 5=-CAUCAUUUCCCUACCUG-CUCCUCCU.
Briefly, when cells that were passaged into 15 cm dishes reached 50 -70% confluence, each dish received 25 ml of starvation media containing high-glucose DMEM, D-valine, 1% antibiotic/antimycotic, transferrin (4 g/ml), fatty acid-free BSA (20 g/ml), and indomethacin (0.1 M). Indomethacin was added separately to media on the day of the starvation treatment. After 2 h at 37°C, cells were transfected with either Stealth RNAi negative control duplexes (Invitrogen) as a control for sequence-independent effects or with a combination of the four selected Stealth RNAi siRNA duplexes targeting C6orf176. siRNA-containing mixtures were added drop-wise to tubes containing Lipofectamine 2000 and incubated for 30 min at room temperature. Subsequently, the solutions were added drop-wise to the dishes containing hCSM cells in starvation medium followed by incubation at 37°C for 46 h. Then the medium was exchanged with incubation medium containing high-glucose DMEM, D-valine, 1% antibiotic/antimycotic, transferrin (4 g/ml), and the EP2 agonist AGN007 (0.2 M). Following incubation at 37°C for 2 h, total RNA from hCSM cells was extracted as described above. C6orf176 knockdown efficiency was monitored by qRT-PCR using the commercially available C6orf176-specific primer and probe set (TaqMan Gene Expression Assay Hs00293257_m1; Applied Biosystems). Other predesigned TaqMan Gene Expression Assays that were used to evaluate effects of C6orf176 knock-down on gene expression of selected downstream cAMP signaling-responsive genes identified previously (19) are shown in Table 2 . Quantitative real-time RT-PCR analysis was performed as described above based on RNA materials derived from three biologically independent experiments.
RESULTS

Time course analysis of C6orf176 expression in response to
EP2 and EP4 agonist stimulation of hCSM cells. The effect of treatment with the EP2 agonist AGN007 (0.2 M) or the EP4 agonist AGN008 (0.2 M) was monitored by changes of C6orf176 tv1 mRNA transcript levels compared with untreated control (DMSO only) in hCSM cells. As described previously, this primary cell line expresses high levels of EP2 and EP4 receptors (19) . Transcriptional regulation was evaluated using qRT-PCR in time course experiments over a 24 h period (Fig. 1) . At the 2 h time point of EP2 or EP4 agonist treatment, a robust peak transcriptional upregulation with a fold change (Ϯ SE) of 2,585 Ϯ 748 or 3,944 Ϯ 750, respectively, was observed. Average C t values (Ϯ SE) at this time point were 22.0 Ϯ 0.5 (EP2 agonist), 21.6 Ϯ 0.2 (EP4 agonist), and 33.3 Ϯ 0.5 (DMSO). In comparison, the C t values for betaactin and GAPDH, used as controls for normalization purposes, were 17.2 Ϯ 0.5 and 16.1 Ϯ 0.3 (EP2 agonist), 17.7 Ϯ 0.4 and 16.5 Ϯ 0.2 (EP4 agonist), and 17.3 Ϯ 0.3 and 16.4 Ϯ 0.2 (DMSO), respectively, demonstrating no significant change in these housekeeping genes subsequent to EP2 or EP4 agonist treatment. The peak transcriptional upregulation at the 2 h time point was followed by a rapid decline but to still substantially elevated baseline transcript levels, ranging between 144-and 342-fold transcriptional upregulation at the 6, 10, and 24 h time points.
C6orf176 transcriptional upregulation subsequent to induction of cAMP signaling in various cell types and by various agents.
The 2 h time point was chosen to determine the change in C6orf176 RNA transcript levels in hCSM cells treated with various known IOP-lowering agents. The dopamine DRD2 receptor agonist QDC and the thromboxane A2 receptor agonist U46619 were used as controls and are not IOP-lowering agents. Four of the eight agents tested that are known cAMP signaling-inducing agents (PGE 2 , BW 245C, carbacyclin, forskolin), in addition to our EP2 and EP4 agonists, also substantially upregulated C6orf176 tv1 gene expression (Fig. 2) . Those agents that activate other signaling pathways did not upregulate C6orf176 tv1 transcript levels (brimonidine tartrate) or only minimally (PGF2␣, 3.1 Ϯ 0.9; U46619, 17.0 Ϯ 9.2; and QDC, 1.9 Ϯ 0.5).
Next we evaluated a subset of compounds (AGN007, AGN008, PGF2␣, carbacyclin, QDC, and forskolin) in respect to C6orf176 tv1 transcript levels in two other ocular cell lines, the trabecular meshwork (TM86) and retinal pigment epithelial (ARPE-19) cell lines. Results for 2 h treatments are shown in Table 3 , compared with data obtained with hCSM cells. Substantial transcriptional upregulation of C6orf176 tv1 was also observed in TM86 cells in response to cAMP signal-inducing agents. For the EP2 agonist, average C t values (Ϯ SE) were 22.8 Ϯ 0.3, and 23.2 Ϯ 0.5 for the EP4 agonist. However, in TM86 cells, upregulation by the EP4 agonist appeared less pronounced than with the EP2 agonist, possibly due to lower EP4 receptor cell surface densities in TM86 cells. In ARPE-19 cells, exposure to cAMP signal-inducing agents resulted in less-pronounced C6orf176 tv1 upregulation. Interestingly in this cell line, a clear difference in responses was seen between the EP2 and EP4 agonists, as well as a rather modest response to carbacyclin stimulation.
Using real-time RT-PCR we found that receptor transcript levels overall correlated with the magnitude of C6orf176 tv1 transcriptional upregulation. The following rank order of receptor expression within the cell types tested was established: TM Ͼ CSM ϾϾ ARPE-19 Ͼ HEK-293 for the EP2 receptor, and CSM ϳ TM Ͼ ARPE-19 ϾϾ HEK-293 for the EP4 receptor.
Inducibility of C6orf176 transcript variants and two genes in antisense orientation subsequent to cAMP signaling. To evaluate expression of different known and putative C6orf176 transcript variants, as well as two nearby genes in antisense orientation that partially overlap the transcribed C6orf176 exon 1 region, additional qRT-PCR primer and probe sets were custom-designed (Table 1 ). These include primer and probe sets to monitor transcription of C6orf176 tv2 (set a), a putative alternatively spliced exon (set b) based on expressed sequence tag sequence information, and an Image cDNA clone (accession number: CB985684), the hypothetical gene LOC441177 based on an Image cDNA clone (accession number: BC110806) in antisense orientation that partially overlaps the transcribed C6orf176 exon 1 region (set c), and another putative gene in antisense orientation (hmm409034) located ϳ3.5 kb further upstream (set d). Table 4 shows results from real-time RT-PCR experiments performed on total RNA obtained from the "drug profiling" studies described above at the 2 h time point using primary cultures of hCSM cells. Agents that are able to activate the cAMP signaling pathway (EP2 and EP4 agonists, carbacyclin, forskolin) induced transcription in a qualitatively similar fashion, albeit to a lesser degree, than observed with the commercially available primer and probe set for C6orf176, which monitors tv1. This includes the two genes expressed in antisense orientation (sets c and d). Thus, concomitant upregulation of LOC441177, whose transcription start site lies within the transcribed C6orf176 exon 1 region in antisense orientation, allows dsRNA formation within the overlap. Inducible presence of the putative alternatively spliced exon (monitored with set b) confirms the existence of an additional transcript variant. The substantial transcriptional upregulation at or near the C6orf176 gene locus is likely due to presence of a large number of CREB binding sites (CRE). The multiple CRE full-site and half-site sequences (29) identified within the promoter region as well as the transcribed C6orf176 gene locus, including intragenic regions, are summarized in Table 5 . Fig. 2 . Profiling of C6orf176 tv1 transcriptional regulation in hCSM cells subsequent to stimulation by various agents for 2 h. All agents were used at a 1 M concentration, with the exception of forskolin, which was at 5 M. Average ratios (treated vs. untreated) and SE as determined by real-time RT-PCR analysis are shown (triplicate analysis). P values are based on 2-sided 2-sample Student's t-tests for the null hypothesis of no difference: * for Յ 0.05 (statistically significant), ** for Յ 0.01 (statistically highly significant), and *** for Յ 0.001 (statistically extremely significant). 
Identification of multiple inducible C6orf176 transcript variants by Northern blot analysis.
To examine the effect of human EP2 receptor stimulation on the induction of C6orf176 expression, HEK-293/hEP2 were treated with the EP2 agonist AGN007 for 2 h. Northern blot analysis using a C6orf176 exon 1-specific radioactive antisense probe revealed induction of several C6orf176 transcript variants of various length and abundance (Fig. 3) . Three major variants of ϳ3.5, 3, and 1.1 kb were observed, the 3.5 kb long transcript variant being the predominant one. Additional bands corresponding to transcript variants of ϳ10, 7, 5.5, 5, and 4.5 kb were also seen. In HEK-293 Naïve control cells treated with DMSO, no C6orf176 transcripts were detected in this Northern blot analysis.
Identification of novel C6orf176 transcript variants by sequencing of cDNA clones obtained from a cDNA library screen.
To elucidate the identity of inducible C6orf176 transcripts, a cDNA library was constructed based on mRNA extracted from hCSM cells after 2 h treatment with the EP2 All agents were used as described in Table 1 . Average ratios (treated vs. untreated), SE, and P values are displayed. Primer and probe sets monitor transcription of C6orf176 tv2 (set a), a putative alternatively spliced exon (set b), LOC441177 (set c), and hmm409034 (set d). n/c, Nonconclusive. Promotor region 3048  1095  493  26499  9560  2462  14315  3048  14831  9372  19720  18008  20753  19474  25352  22024  34659  22989  37912  24087  39139  26499  43254  29023  43535  33727  44529  35888  46572  36540  53806  40922  55334  43538  55470  48325  62282  57039  58567 cAMP-response element binding protein binding (CRE) full-site (TGACGTCA) and half-site (TGACG/CGTCA) sequences identified are listed in relative position to the start of C6orf176 tv1 and tv2. We analyzed 9 kb of promoter context sequence as well as 65 kb of the transcribed C6orf176 gene locus. For CRE full sites, 1 mismatch was allowed. agonist AGN007. Colony hybridization of the cDNA library using a C6orf176 exon 1-specific 32 P-labeled probe identified positive cDNA clones (Fig. 4) , including one C6orf176 tv1, two clones of tv1 with a 61 nt extended 5= sequence, as well as a new, 1,675 nt long transcript variant (termed tv3) that uses an alternate exon in its 3=-end. Tv3 maps ϳ2 kb downstream of the alternate exon used by tv2, extending the transcribed C6orf176 genomic locus to ϳ67 kb.
C6orf176 transcribed region
Identification of modulation of expression of cAMP signaling-responsive genes due to siRNA-mediated knock-down of C6orf176. RNAi was used to evaluate effects of C6orf176 gene silencing in presence of the EP2 agonist AGN007 (0.2 M, 2 h) in hCSM cells. A combination of gene-specific siRNA duplexes was selected and compared with unrelated negative control duplexes. C6orf176 silencing efficiency was 77% (0.23-fold change) in EP2 agonist-treated cells as determined by quantitative real-time RT-PCR analysis. Transcript levels of beta-actin and GAPDH control housekeeping genes were essentially unaffected. Average Ct and calculated fold change values are given in Table 6 .
To evaluate a possible regulatory role of C6orf176 in cAMPmediated gene expression, the effect of C6orf176 gene silencing upon transcript levels of several other genes, selected from a small group of downstream cAMP signaling-responsive genes identified previously (19) , was then investigated using qRT-PCR. Six genes were identified, out of 27 analyzed, that revealed a statistically significant modulation of their expression levels due to the knock-down of C6orf176 (Table 7) . These included the transcription factors NR4A3 and NR4A1, (nuclear receptor subfamily 4, group A, member 1 and 3, respectively), the osmolarity regulator AVPI1 (arginine vasopressin-induced 1), the extracellular matrix (ECM)-associated cell adhesion gene CRISPLD2 (cysteine-rich secretory protein LCCL domain containing 2), the ECM remodeling factor CHST6 [carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6], as well as a novel gene of unknown function, Average threshold cycle (AVG Ct) values were determined by quantitative real-time RT-PCR for C6orf176 tv1 as well as beta-actin and GAPDH housekeeping genes in hCSM cells. Cells were exposed to the EP2 agonist AGN007 (0.2 M; 2 h) after transfection with either negative control siRNA duplexes or C6orf176-specific siRNA duplexes. Fold change calculations of gene expression ratios due to knock-down (C6orf176-specific siRNA duplexes vs. unrelated negative control duplexes) are based on 3 independent experiments. Average ratios (AVG) of treated vs. control samples as well as SE are displayed. P values are based on 2-sided 2-sample Student's t-tests for the null hypothesis of no difference: ***for Յ0.001 (statistically extremely significant). 
DISCUSSION
Previous microarray-and qRT-PCR-based gene regulation profiling experiments identified C6orf176 as the most highly upregulated gene in hCSM cells following treatment with either EP2 (AGN007) and EP4 (AGN008) agonists and established that the cAMP pathway is the most important one in hCSM cells subsequent to EP2 and EP4 receptor stimulation (19) . Systematic time course experiments over a 24 h period identified the highest upregulation of C6orf176 at the 2 h time point (ϳ2,600-and ϳ3,900-fold, respectively), monitoring expression levels of tv1 by qRT-PCR. The rapid and pronounced transcriptional upregulation followed by a brisk decline to elevated baseline transcript levels resembles kinetics of early response genes that are often transcription (co-)factors that have regulatory function upon expression of downstream genes. C6orf176 transcript levels remained significantly upregulated at the 6, 10, and 24 h time points, reflecting the continuous exposure to the EP2 or EP4 agonists.
C6orf176 tv1 transcriptional upregulation was more pronounced in response to the EP4 agonist than to the EP2 agonist in hCSM and ARPE-19 cells, which correlates with relative receptor transcript levels. In TM86 cells, the EP4 agonist upregulated C6orf176 less than the EP2 agonist, also reflecting receptor transcript levels. Other agents known to activate the cAMP signaling pathway also sharply induced C6orf176 transcription.
Furthermore, we have identified multiple C6orf176 transcript variants in HEK-293/hEP2 cells following stimulation of the EP2 receptor. After treatment with the EP2 agonist AGN007, at least 10 discernible bands were observed, in addition to signals suggestive of transcripts of variable length possibly due to the existence of putative alternative transcription start sites (or regions). The official tv1 has a length of 1,832 bp and is recognizable as part of the signal area corresponding to RNA sizes between 1.5 and 2.5 kb in length; tv2 has a length of 1,123 bp and is detectable as a major band on the film.
Existence of additional inducible transcript variants subsequent to EP2 agonist treatment and cAMP signaling may challenge NCBI's reclassification of the C6orf176 gene as a purely ncRNA. Sequence analysis of new transcript variants identified existence of additional ORFs and corresponding protein candidates that might be able to serve as future drug targets to manipulate the cAMP signaling pathway. Existence of any of those protein candidates, however, requires experimental verification, particularly as translation start sites are not embedded within canonical Kozak consensus sequence environments.
Using qRT-PCR we evaluated consequences of RNAi-based C6orf176 gene silencing. We selected several genes, putative key players mediating physiological IOP-lowering effects, from a larger group of downstream cAMP signaling-responsive genes identified previously (19) for analysis. However, presumably due to prevalence of very high transcript levels subsequent to EP2 agonist treatment, C6orf176 silencing efficiency was significant but incomplete (77%). Nevertheless, for six genes (including the osmolarity regulator AVPI1, the ECM adhesion molecule CRISPLD2, and the ECM remodeling factor CHST6), knock-down of C6orf176 resulted in a modest additional transcriptional upregulation between 1.4-and 3.4-fold. This observation establishes proof-of-principle for a possible regulatory function of C6orf176 upon expression of genes that are part of cell type-specific networks mediating physiological effects in response to cAMP signaling.
Reclassified by NCBI as an ncRNA, C6orf176 belongs to a new class of functional transcripts emerging as important negative or positive regulators of gene expression in many organisms. Recent transcriptomic and bioinformatic studies have identified a surprisingly large number of ncRNAs in eukaryotic cells and suggest existence of thousands of ncRNAs within the human genome (1, 2, 5, 14, 25) . The observed transcript sizes categorize C6orf176 transcripts as long ncRNAs, which, for example, have been shown to be involved in epigenetic regulation, such as the 2.2 kb long noncoding (lnc) RNA termed HOTAIR (20) . C6orf176 appears to exert a negative regulatory effect upon expression of the target genes identified subsequent to RNAi-based C6orf176 gene silencing. Although unexpected given the early induction of C6orf176 expression due to cAMP signaling pathway activation, it may Quantitative real time RT-PCR analysis was performed for each gene of interest in hCSM cells based on RNA materials derived from 3 biologically independent experiments. Fold changes of gene expression were calculated subsequent to knock-down of C6orf176 (C6orf176-specific siRNA duplexes vs. unrelated negative control duplexes) in presence of the EP2 agonist AGN007 (0.2 M; 2 h). Average ratios (AVG) of knock-down vs. control samples, SE, as well as P values are displayed.
be indicative of a negative feedback loop that fine-tunes the expression response of downstream target genes. However, as the subset of cAMP-responsive genes analyzed was small, a possible role as transcription enhancer, which has been described for some lncRNAs (7, 16) , cannot be ruled out.
Increasing numbers of natural sense-antisense transcript pairs are being identified in a variety of prokaryotic and eukaryotic organisms (12, 17, 26, 28) . The distribution of antisense transcripts is distinct from that of sense transcripts and is nonrandom across the human genome and different among cell types, which suggests that they are a fundamental component of gene regulation (8) . It is possible that different transcript variants could mediate regulation of different gene subsets that may be involved in mediating the IOP-lowering effects via the uveo-scleral outflow path subsequent to EP2 and EP4 receptor stimulation and activation of the cAMP signaling pathway.
Whether C6orf176 transcript variants are in fact noncoding, protein-coding, or a combination thereof awaits further experimental evidence, along with sequence identification of larger transcripts variants as observed by Northern blot analysis. C6orf176 should be useful as a biomarker, e.g., by measuring expression levels in context with disease-dependent deregulation of the cAMP signaling pathway, as a novel drug target, and/or as a model system for studying transcriptional regulation by chromatin and RNA polymerase II.
